Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Moderna Submits RSV Vaccine in Japan
May 31, 2024
-
REGULATORY Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
-
BUSINESS Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
-
BUSINESS AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
-
BUSINESS Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
-
BUSINESS Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
-
BUSINESS MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
-
REGULATORY LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
-
ORGANIZATION JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
-
BUSINESS Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
-
REGULATORY Japan Govt to Launch Public-Private Forum to Attract Investments
May 23, 2024
-
BUSINESS AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
-
BUSINESS Servier Trains Sight on 50% Oncology Sales Ratio by 2030, Set to Upsize Japan Biz
May 22, 2024
-
REGULATORY Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
-
REGULATORY Bridion Sees Rare May Generic Entry for New Dosage Form in Japan
May 21, 2024
-
REGULATORY Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
-
BUSINESS Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
-
BUSINESS Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
-
REGULATORY Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
-
REGULATORY First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…